Cyclic oligoadenylate signalling mediates Mycobacterium tuberculosis CRISPR defence
S. Grüschow, J. S. Athukoralage, S. Graham, T. Hoogeboom, M. F. White
This study shows that Mycobacterium tuberculosis uses a type III-A CRISPR system with a cyclic hexa-adenylate (cA6) signalling pathway and the Csm6 ribonuclease for immunity against mobile genetic elements, rather than DNA cleavage.
bioRxiv · Jun 12, 2019Biochemistry